Results 201 to 210 of about 37,664 (239)

GALNT3 is a novel target driving lymphomagenesis via O-glycosylation of FGFR2. [PDF]

Cell Commun Signal
Sun R, Wang W, Gao Y, Aximujiang K, Li Y, Innocent A, Xu Z, Ma J.   +7 more
europepmc   +1 more source

Prenatal diagnosis of apert syndrome at 23 weeks: a case report with isolated syndactyly and sacrococcygeal appendage preceding cranial malformation. [PDF]

AME Case Rep
Ge S, Lai Q, Yuan D, McGrath E.
europepmc   +1 more source

Role of lipid rafts in the FGFR2c-mediated oncogenic signaling by involvement of TRPA1 channel in pancreatic ductal adenocarcinoma cells. [PDF]

Cell Death Dis
Mancini V, Manganelli V, Garofalo T, Sorice M, Raffa S, Scullari D, Ranieri D, Belleudi F.   +7 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

FGFR2-IIIb Expression by Immunohistochemistry Has High Specificity in Cholangiocarcinoma with FGFR2 Genomic Alterations

Digestive Diseases and Sciences, 2021
FGFR2 genomic alterations are observed in 10-20% of cholangiocarcinoma (CCA). Although FGFR2 fusions are an important actionable target, FGFR2 protein expression has not been thoroughly characterized.To evaluate FGFR2 protein expression in cholangiocarcinoma harboring FGFR2 genomic alterations.FGFR2 protein expression was evaluated in 99 CCA cases with
Pedro Usón Junior, Mansi Arora, James Bogenberger   +2 more
exaly   +3 more sources

Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study.

The Lancet Gastroenterology and Hepatology, 2021
BACKGROUND Treatment options are sparse for patients with advanced cholangiocarcinoma after progression on first-line gemcitabine-based therapy.
M. Javle, S. Roychowdhury, R. Kelley, S. Sadeghi, T. Macarulla, K. Weiss, D. Waldschmidt, L. Goyal, I. Borbath, A. El-Khoueiry, M. Borad, W. Yong, P. Philip, M. Bitzer, S. Tanasanvimon, Ai Li, A. Pande, H. Soifer, S. Shepherd, S. Moran, A. Zhu, T. Bekaii-Saab, G. Abou-Alfa   +22 more
semanticscholar   +1 more source

Updated dose escalation results for ReFocus, a first-in-human study of highly selective FGFR2 inhibitor RLY-4008 in cholangiocarcinoma and other solid tumors.

Journal of Clinical Oncology, 2023
4009 Background: Oncogenic FGFR2 alterations (fusions/rearrangements (f/r), amplifications, mutations) represent a broad therapeutic opportunity as they drive multiple solid tumors, particularly cholangiocarcinoma (CCA). However, off-isoform toxicity and
M. Borad, A. Schram, R. Kim, Suneel D. Kamath, V. Sahai, E. Dotan, R. Kelley, M. Ponz-Sarvisé, D. Oh, J. Yachnin, V. Florou, P. Cassier, Joon-Oh Park, C. Liao, Michael Millward, F. T. Ramirez, F. Ricard, A. Hollebecque, V. Subbiah, L. Goyal   +19 more
semanticscholar   +1 more source

Discovery of a Selective and Orally Bioavailable FGFR2 Degrader for Treating Gastric Cancer.

Journal of Medicinal Chemistry, 2023
Abnormal activation of fibroblast growth factor receptors (FGFRs) results in the development and progression of human cancers. FGFR2 is frequently amplified or mutated in cancers; therefore, it is an attractive target for tumor therapy.
Lin Ma, Yingying Li, Ruixiang Luo, Yuhan Wang, Jiaqi Cao, Weitao Fu, Bolan Qian, Lei Zheng, Longguang Tang, Xinting Lv, Lulu Zheng, Guang Liang, Lingfeng Chen   +12 more
semanticscholar   +1 more source

A novel mutation in FGFR2

American Journal of Medical Genetics Part A, 2014
Craniosynostosis is a congenital anomaly that can occur as an isolated condition or as part of a syndrome. Although several genes are known to cause syndromic craniosynostosis, only 24% can be attributed to known genes. Therefore, it is likely that more mutations and other genes are involved.
Goos, Jacqueline, van den Ouweland, Ans, Swagemakers, Sigrid, Verkerk, Annemieke, Hoogeboom, Jeannette, van Veelen - Vincent, M.L.C., Mathijssen, Irene, van der Spek, Peter   +7 more
openaire   +3 more sources

Modulation of the expression of the FGFR2-IIIb and FGFR2-IIIc molecules in dermatofibroma

Journal of Dermatological Science, 2008
[No abstract available]
SKROZA, Nevena, Sabrina Rotolo, CECCARELLI, SIMONA, ROMANO, Ferdinando, Daniele Innocenzi, FRATI, Luigi, ANGELONI, Antonio, MARCHESE, Cinzia   +7 more
openaire   +3 more sources

Updated results of the FOENIX-CCA2 trial: Efficacy and safety of futibatinib in intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions/rearrangements.

Journal of Clinical Oncology, 2022
4009 Background: Survival outcomes are historically poor in patients (pts) with advanced/metastatic iCCA, with median overall survival (mOS) times of approximately 1 year with first-line gemcitabine plus cisplatin and approximately 6 months with second ...
L. Goyal, F. Meric-Bernstam, A. Hollebecque, C. Morizane, J. Valle, T. Karasic, T. Abrams, R. Kelley, P. Cassier, J. Furuse, H. Klümpen, H. Chang, Li‐Tzong Chen, Y. Komatsu, K. Masuda, D. Ahn, Kate Li, K. Benhadji, V. Wacheck, J. Bridgewater   +19 more
semanticscholar   +1 more source